Document is current

Any future updates will be listed below

Matters arising: On the cost-effectiveness for the Italian National Health Service of nab-paclitaxel plus gemcitabine vs gemcitabine alone in metastatic pancreatic cancer

Crossref DOI link: https://doi.org/10.1186/s42506-024-00179-3

Published Online: 2024-12-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark